CD20-directed Antibody Interactions

CD20-directed Cytolytic Antibody

Demyelinating Diseases

Multiple Sclerosis, Chronic Progressive

Multiple Sclerosis, Relapsing-Remitting

<section class="Section" data-sectioncode="34089-3"><a name="s57"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Ublituximab-xiiy is a recombinant chimeric monoclonal IgG1 antibody with reduced fucose content directed against CD20-expressing B-cells. The molecular weight of the antibody is approximately 147 kDa.</p><p>BRIUMVI (ublituximab-xiiy) injection for intravenous infusion is a sterile, clear to opalescent, colorless to slightly yellow, preservative-free solution. Each mL of solution contains 25 mg ublituximab-xiiy, 0.4 mg hydrochloric acid, 0.7 mg polysorbate 80, 9.0 mg sodium chloride, 6.4 mg sodium citrate, and Water for Injection, USP. The pH is 6.5.</p></section>

BRIUMVI

ublituximab-xiiy

ublituximab

6 ML ublituximab-xiiy 25 MG/ML Injection

Briumvi

6 ML ublituximab-xiiy 25 MG/ML Injection [Briumvi]

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

How To Order Briumvi

Billing & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Briumvi Start Form 

Enroll in Patient Savings Program - Only HCP can enroll patients 

Patient Asssitance Program 

Infusion Center Locator 

About Briumvi

Side Effects 

Receiving Briumvi

Infusion Experience 

Briumvi Patient Support Program 

Instructions For Use: Multiple Sclerosis

Patient Brochure 

Patient Brochure - Spanish

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Briumvi prior authorization forms by payer